The purpose of this study is to determine whether nabilone (Cesamet) when used as an adjunctive agent with gabapentin (Neurontin) provides significantly improved pain relief over gabapentin alone for the management of neuropathic pain in MS.

Neuropathic pain syndromes, which occur due to damage to central and/or peripheral nerve axons, are often more difficult to manage and are commonly refractory to the conventional analgesia approach described by the World Health Organization, including NSAIDs and narcotic agents. These pain syndromes are often described by symptoms of burning, stabbing, crawling, shock-like, numbness and/or tingling, and can be quite concerning to the patient, especially when there is an inadequate response to treatment. It has been estimated that the prevalence of chronic pain in MS ranges anywhere from 30-90%, placing it as the second worst disease-induced symptom experienced by this patient population.

The pathophysiologic causes of this pain syndrome are complex and multifaceted, with no one specific link attributed to the pain response. Due to the complexity of neuropathic pain - which is only partially understood at best - it may be necessary in many cases to treat the source of the pain with more than one agent in order to address the many different contributors to this pain process. More thorough review of how the currently available agents for NPP work together would provide clinicians with safety and efficacy data which would aid in providing optimal pain management.

Inclusion Criteria:

• Males and females between the ages of 18-65 years old with clinically definite RRMS
• EDSS of < 6.5
• Current treatment with gabapentin that is not effective at a stabilized dose of (>1800mg/day) for at least 1 month.
• Visual Analogue Scale score for NPP symptoms > 5; pain present for at least 3 months
• Negative serum pregnancy test for all females of childbearing age; not currently breastfeeding
• No history of alcohol or substance abuse
• No history of non-psychotic emotional disorders
• No significant hepatic or renal insufficiency
• No significant cardiovascular disease or hypertension
• No known hypersensitivity and/or allergy to nabilone or its derivatives
• No current use of cannabinoid or related products